{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:06:46Z","timestamp":1773407206609,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1684\/bdc.2010.1083","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T16:01:59Z","timestamp":1565712119000},"page":"445-451","source":"Crossref","is-referenced-by-count":3,"title":["Facteurs pronostiques et survie des cancers colorectaux m\u00e9tastatiques au CHU de Sousse (Tunisie) : \u00c9tude comparative de deux p\u00e9riodes de traitement de 200 patients"],"prefix":"10.1016","volume":"97","author":[{"given":"O.","family":"Gharbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Chabchoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Limam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hochlef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ben Fatma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Landolsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gahbiche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Braham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mokni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ajmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Letaief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ben Hadj Hamida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ben Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2010.1083_bib0005","first-page":"100","article-title":"Le cancer dans le centre tunisien","author":"Korbi","year":"1995","journal-title":"Sousse: \u00c9dition copie"},{"key":"10.1684\/bdc.2010.1083_bib0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irrinotecan versus fluouracil by continuous trial of irrinotecan after fluouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1684\/bdc.2010.1083_bib0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluouracil compared with fluouracil alone as first line treatment for metastatic colorectal cancer- a multicenter randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1684\/bdc.2010.1083_bib0020","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer","volume":"18","author":"De Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1083_bib0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1684\/bdc.2010.1031","article-title":"Pr\u00e9requis avant l\u2019administration et pr\u00e9vention des effets secondaires d\u2019une chimioth\u00e9rapie pour cancer colorectal","volume":"97","author":"Bouch\u00e9","year":"2010","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2010.1083_bib0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"Folfiri followed by folfox 6 or the reverse sequence in advanced colorectal cancer. A randomized Gercor study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2010.1083_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized trial of fluouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1684\/bdc.2010.1083_bib0040","first-page":"S11","article-title":"R\u00e9flexion sur la bonne strat\u00e9gie d\u2019utilisation de l\u2019oxaliplatine avec le 5-fluorouracil et ses d\u00e9riv\u00e9s dans le cancer colorectal avanc\u00e9","volume":"93","author":"Tournigand","year":"2006","journal-title":"Bull Cancer"},{"key":"10.1684\/bdc.2010.1083_bib0045","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/annonc\/mdf034","article-title":"Clinical derminants of survival in patients with 5-fluouracil based treatment for metastatic colorectal cancer: results of multivariate analysis of 3825 patients","volume":"13","author":"K\u00f6hne","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2010.1083_bib0050","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluouracil and leucovorin for metastatic colorectal","volume":"343","author":"Saltz","year":"2000","journal-title":"N Eng J Med"},{"key":"10.1684\/bdc.2010.1083_bib0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/annonc\/mdg724","article-title":"Irinotecan in metastatic colorectal cancer : dose intensification and combination with new agents, including biological response modifiers","volume":"14","author":"Ducreux","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2010.1083_bib0060","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","article-title":"Long-term survival of patients with unresecable colorectal cancer liver metastases following infusional chemotherapy with 5-fluouracil, leucovorin, oxaliplatin and surgery","volume":"10","author":"Giacchtti","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2010.1083_bib0065","first-page":"2532","article-title":"A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluouracil and leucovorin as initial treatment of patients with metastatic colorectal carcinoma","volume":"85","author":"Levi","year":"1999","journal-title":"International Organization for cancer chronotherapy. Cancer"},{"key":"10.1684\/bdc.2010.1083_bib0070","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10434-001-0347-3","article-title":"Five-year survival following hepatic resection after neoadjuvant therapy for nonresecable colorectal liver metastases","volume":"8","author":"Adam","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1684\/bdc.2010.1083_bib0075","first-page":"278","article-title":"Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns recurrence","volume":"100","author":"Kevin","year":"1986","journal-title":"Surgery"},{"key":"10.1684\/bdc.2010.1083_bib0080","first-page":"1","article-title":"R\u00e9section des m\u00e9tastases h\u00e9patiques d\u2019origine colorectale apr\u00e8s chimioth\u00e9rapie par Irinot\u00e9can","volume":"129","author":"Adam","year":"2004","journal-title":"Ann Chir"},{"key":"10.1684\/bdc.2010.1083_bib0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdg731","article-title":"Chemotherapy and surgery: new perspectives on the treatment of unresecable liver metastases","volume":"14","author":"Adam","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2010.1083_bib0090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunnigham","year":"2004","journal-title":"N Eng J Med"},{"key":"10.1684\/bdc.2010.1083_bib0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.critrevonc.2004.05.005","article-title":"Predictive factors for response to chemotherapy in colorectal cancer patients","volume":"52","author":"Vincenzi","year":"2004","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115308584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115308584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T04:48:51Z","timestamp":1602478131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115308584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0007455115308584"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2010.1083","relation":{"is-cited-by":[{"id-type":"doi","id":"10.4251\/wjgo.v4.i4.71","asserted-by":"object"}]},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}